Remove Healthcare Remove Pharma Remove Pharmaceutical manufacturing Remove Prescription
article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. Hedley Rees has written a book on pharma supply chains that is eye-opening and downright scary. Can patients really be confident in pharma supply chains? Why would a pharma company take risks like these? Patients should be scared.

article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. Actavis, 570 U.S. 136 (2013), [link] opinions/12pdf/12-416_m5n0.pdf.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A Powerful Point-of-Sale Partnership that Delivers on the Promise of Affordable Insulin

PM360

In March of this year the three largest insulin manufacturers announced a dramatic reduction in the price of many commonly prescribed insulins and a monthly out-of-pocket (OOP) cap of $35 that went into effect in May. The price is available to cash-paying patients with a valid prescription. for only $35. References: 1.

Retail 52
article thumbnail

10 New Solutions, Strategies, and Devices to Boost Adherence

PM360

One reason for this growth is an increasing demand for personalized healthcare technologies as patients look for advances in how healthcare is delivered following the pandemic. Unlike other formulary optimization solutions, Levrx delivers plan-specific and real-time prescription insights. billion in 2030 at a CAGR of 9.2%.

article thumbnail

Everything You Need to Know About Market Access in China

PM360

Given China’s status as the world’s second most populous nation and an economic powerhouse, it represents both a monumental market opportunity and a dynamic arena of challenges for pharmaceutical products. In 2021, the out-of-pocket (OOP) cost accounts for 28% of the whole healthcare expenses compared to 15.4% billion people in 2023).

Marketing 105
article thumbnail

Diversity and inclusion in oncology clinical trials

Clarify Health

In this blog, we take a close look at health equity in oncology trials specifically, assessing how the lack of diversity and inclusion has impacted cancer patients and the pharma industry’s key initiatives to address it. Clarify launched its real-world evidence on health disparities in 2021.